---
title: "Xtandi (enzalutamide), all indications: Safety questions"
description: "Safety questions on Xtandi (enzalutamide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Does Xtandi prolong the QT interval? What are the contraindications for Xtandi? What are the warnings and precautions for Xtandi? Can Xtandi cause seizures? 10 further questions follow. 14 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xtandi/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide), all indications: Safety questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)  
Indication pages: [Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)

## Safety

<a id="xtandi-qt-interval"></a>

### Does Xtandi prolong the QT interval?

> “At the recommended dosage, XTANDI does not cause large mean increases (i.e., > 20 msec) in the QT interval.”

Source: [XTANDI: Prescribing information, page 17, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=17)

<a id="xtandi-overdose"></a>

### What should be done after an Xtandi overdose?

> “In the event of an overdosage, stop treatment with XTANDI and initiate general supportive measures taking into 
> consideration the half-life of 5.8 days. In a dose escalation study, no seizures were reported at < 240 mg daily, whereas 
> 3 seizures were reported, 1 each at 360 mg, 480 mg, and 600 mg daily. Patients may be at increased risk of seizure 
> following an overdosage.”

Source: [XTANDI: Prescribing information, page 16, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=16)

## Warnings

<a id="xtandi-contraindications"></a>

### What are the contraindications for Xtandi?

> “4 CONTRAINDICATIONS 
> None.”

Source: [XTANDI: Prescribing information, page 3, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=3)

<a id="xtandi-warnings-precautions"></a>

### What are the warnings and precautions for Xtandi?

> “SUMMARY OF WARNINGS AND PRECAUTIONS
> Seizure occurred in 0.6% of patients receiving XTANDI. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue XTANDI in patients who develop a seizure during treatment.
> Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI.
> Hypersensitivity: Discontinue XTANDI.
> Ischemic Heart Disease: Optimize management of cardiovascular risk factors. Discontinue XTANDI for Grade 3-4 adverse reactions.
> Falls and Fractures: Evaluate patients for fracture and fall risk, and treat patients with bone-targeted agents according to established guidelines.
> Embryo-Fetal Toxicity: XTANDI can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception.
> Severe Dysphagia or Choking Related to Product Size: Consider using smaller XTANDI tablet(s) in patients who have difficulty swallowing. Discontinue XTANDI for patients who cannot swallow capsules or tablets.
> Interference with Immunoassay Measurement of Digoxin: XTANDI can interfere with certain digoxin immunoassays, resulting in falsely elevated digoxin plasma concentration results.”

Source: [XTANDI: XTANDI® (enzalutamide), captured 2026-11-13](https://www.xtandihcp.com/#:~:text=SUMMARY%20OF%20WARNINGS%20AND%20PRECAUTIONS,elevated%20digoxin%20plasma%20concentration%20results.)

<a id="xtandi-seizure"></a>

### Can Xtandi cause seizures?

> “Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In these trials, patients with 
> predisposing factors for seizure were generally excluded. Seizure occurred from 13 to 2250 days after initiation of 
> XTANDI. Patients experiencing seizure were permanently discontinued from therapy, and all seizure events resolved. 
> In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 
> (2.2%) XTANDI-treated patients experienced a seizure. Three of the 8 patients experienced a second seizure during 
> continued treatment with XTANDI after their first seizure resolved. It is unknown whether anti-epileptic medications will 
> prevent seizures with XTANDI. Patients in the study had one or more of the following pre-disposing factors: the use of 
> medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of 
> cerebrovascular accident or transient ischemic attack (~ 24%), and Alzheimer’s disease, meningioma, or leptomeningeal 
> disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, 
> presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection 
> (all < 5%). Approximately 17% of patients had more than one risk factor. 
> Advise patients of the risk of developing a seizure while receiving XTANDI and of engaging in any activity where sudden 
> loss of consciousness could cause serious harm to themselves or others. 
> Permanently discontinue XTANDI in patients who develop a seizure during treatment.”

Source: [XTANDI: Prescribing information, page 3, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=3)

Note: The Prescribing Information pools its eight randomized, controlled trials across patients with CRPC (N = 3651), mCSPC (N = 754), and nmCSPC with high-risk BCR (N = 707).

<a id="xtandi-pres"></a>

### Can Xtandi cause PRES (posterior reversible encephalopathy syndrome)?

> “There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving XTANDI 
> [see Adverse Reactions (6.2)]. PRES is a neurological disorder which can present with rapidly evolving symptoms 
> including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or 
> without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic 
> resonance imaging (MRI). Discontinue XTANDI in patients who develop PRES.”

Source: [XTANDI: Prescribing information, page 3, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=3)

<a id="xtandi-allergic-reactions"></a>

### Can Xtandi cause allergic reactions or facial swelling?

> “Hypersensitivity reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with 
> enzalutamide in eight randomized clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise 
> patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek 
> medical care. Permanently discontinue XTANDI for serious hypersensitivity reactions.”

Source: [XTANDI: Prescribing information, page 3, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=3)

Note: The Prescribing Information pools its eight randomized, controlled trials across patients with CRPC (N = 3651), mCSPC (N = 754), and nmCSPC with high-risk BCR (N = 707).

<a id="xtandi-heart-disease"></a>

### Does Xtandi increase the risk of ischemic heart disease?

> “In the combined data of five randomized, placebo-controlled clinical studies, ischemic heart disease occurred more 
> commonly in patients on the XTANDI arm compared to patients on the placebo arm (3.5% vs 2%). Grade 3-4 ischemic 
> events occurred in 1.8% of patients on the XTANDI arm compared to 1.1% on the placebo arm. Ischemic events led to 
> death in 0.4% of patients on the XTANDI arm compared to 0.1% on the placebo arm. 
> Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as 
> hypertension, diabetes, or dyslipidemia. Discontinue XTANDI for Grade 3-4 ischemic heart disease.”

Source: [XTANDI: Prescribing information, page 4, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=4)

Note: The Prescribing Information names its five placebo-controlled trials as AFFIRM, PROSPER, PREVAIL, ARCHES, and EMBARK; ARCHES and EMBARK enrolled patients with castration-sensitive prostate cancer.

<a id="xtandi-falls-fractures"></a>

### Does Xtandi increase the risk of falls and fractures?

> “Falls and fractures occurred in patients receiving XTANDI. Evaluate patients for fracture and fall risk. Monitor and 
> manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted 
> agents.  
> In the combined data of five randomized, placebo-controlled clinical studies, falls occurred in 12% of patients treated with 
> XTANDI compared to 6% of patients treated with placebo. Falls were not associated with loss of consciousness or 
> seizure. Fractures occurred in 13% of patients treated with XTANDI and in 6% of patients treated with placebo. Grade 3-4 
> fractures occurred in 3.4% of patients treated with XTANDI and in 1.9% of patients treated with placebo. The median 
> time to onset of fracture was 420 days (range: 1 to 2348 days) for patients treated with XTANDI. Routine bone density 
> assessment and treatment of osteoporosis with bone-targeted agents were not performed in the studies.”

Source: [XTANDI: Prescribing information, page 4, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=4)

Note: The Prescribing Information names its five placebo-controlled trials as AFFIRM, PROSPER, PREVAIL, ARCHES, and EMBARK; ARCHES and EMBARK enrolled patients with castration-sensitive prostate cancer.

<a id="xtandi-swallowing-choking"></a>

### Can Xtandi cause choking or trouble swallowing?

> “Severe dysphagia or choking, including events that could be life-threatening requiring medical intervention or fatal, can 
> occur due to XTANDI product size. Advise patients to take each capsule or tablet whole with a sufficient amount of water 
> to ensure that all medication is successfully swallowed. Consider use of a smaller tablet size of XTANDI in patients who 
> have difficulty swallowing. Discontinue XTANDI for patients who cannot swallow capsules or tablets.”

Source: [XTANDI: Prescribing information, page 4, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=4)

## Side effects

<a id="xtandi-high-blood-pressure"></a>

### Does Xtandi raise blood pressure?

> “In the combined data from five randomized placebo-controlled clinical trials, hypertension was reported in 14% of 
> patients receiving XTANDI and 7% of patients receiving placebo. Medical history of hypertension was balanced between 
> arms. Hypertension led to study discontinuation in < 1% of patients in each arm.”

Source: [XTANDI: Prescribing information, page 13, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=13)

Note: The Prescribing Information names its five placebo-controlled trials as AFFIRM, PROSPER, PREVAIL, ARCHES, and EMBARK; ARCHES and EMBARK enrolled patients with castration-sensitive prostate cancer.

<a id="xtandi-common-side-effects"></a>

### What are the most common side effects of Xtandi?

> “In five placebo-controlled trials (AFFIRM, PROSPER, PREVAIL, ARCHES, and EMBARK), the median duration of 
> treatment was 19.4 months (range: < 0.1 to 90.4) in the XTANDI group [see Clinical Studies (14)]. In these five trials, the 
> most common adverse reactions (≥ 10%) that occurred more frequently (≥ 2% over placebo) in the XTANDI-treated 
> patients were musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, 
> hemorrhage, fall, fracture and headache.”

Source: [XTANDI: Prescribing information, page 5, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=5)

Note: The five placebo-controlled trials in this pooled statement include trials in castration-sensitive prostate cancer (ARCHES and EMBARK) as well as CRPC (AFFIRM, PROSPER, and PREVAIL).

<a id="xtandi-lab-abnormalities"></a>

### What lab abnormalities occur with Xtandi?

> “Lab Abnormalities: Lab abnormalities that occurred in ≥ 5% of patients, and more frequently (> 2%) in the XTANDI arm compared to placebo in the pooled, randomized, placebo-controlled studies are hemoglobin decrease, neutrophil count decreased, white blood cell decreased, hyperglycemia, hypermagnesemia, hyponatremia, hypophosphatemia, and hypercalcemia.”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=Lab%20Abnormalities%3A%20Lab%20abnormalities%20that,hypermagnesemia%2C%20hyponatremia%2C%20hypophosphatemia%2C%20and%20hypercalcemia.)

> “Table 8. Laboratory Abnormalities 
>
> XTANDI 
> (N = 3526) 
> Placebo 
> (N = 2636) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> Hematology 
>     Hemoglobin decreased 
> 50 
> 1.8 
> 47 
> 1.5 
>     Neutrophil count decreased 
> 20 
> 1 
> 17 
> 0.5 
>     White blood cell decreased 
> 18 
> 0.5 
> 11 
> 0.2 
> Chemistry 
>     Hyperglycemia 
> 86 
> 3.7 
> 78 
> 4.3 
>     Hypermagnesemia 
> 17 
> 0.1 
> 14 
> 0.3 
>     Hyponatremia 
> 14 
> 1.6 
> 9 
> 1.4 
>     Hypophosphatemia 
> 10 
> 1.4 
> 7 
> 0.8 
>     Hypercalcemia 
> 8 
> 0.1 
> 5 
> 0.1”

Source: [XTANDI: Prescribing information, page 13, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=13)

Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, placebo Grade 1-4, and placebo Grade 3-4 percentages, in that order, as in the table header.

<a id="xtandi-postmarketing-side-effects"></a>

### What side effects have been reported with Xtandi since approval?

> “The following additional adverse reactions have been identified during post-approval use of XTANDI. Because these 
> reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their 
> frequency or establish a causal relationship to drug exposure. 
> Gastrointestinal Disorders: vomiting, dysphagia (including choking related to XTANDI product size) 
> Immune System Disorders: hypersensitivity (edema of the face, tongue, lip, or pharynx) 
> Neurological Disorders: posterior reversible encephalopathy syndrome (PRES), dysgeusia 
> Skin and Subcutaneous Tissue Disorders: rash, severe cutaneous adverse reactions (including Stevens-Johnson syndrome 
> (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms 
> (DRESS) and acute generalized exanthematous pustulosis (AGEP))”

Source: [XTANDI: Prescribing information, page 13, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=13)

## Related pages
- [Medical information: Xtandi (enzalutamide): All indications](https://www.evicenter.com/medical-information/xtandi)
- [Indication](https://www.evicenter.com/medical-information/xtandi/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xtandi/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/xtandi/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xtandi/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xtandi/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xtandi/access-and-coverage)
